Details

Autor(en) / Beteiligte

• Thompson, P.M.
• Seifried, B.A.
• Kyemba, S.K.
• Jensen, S.J.
• Guo, C.
• Maris, J.M.
• Brodeur, G.M.
• Stram, D.O.
• Seeger, R.C.
• Gerbing, R.
• Matthay, K.K.
• Matise, T.C.
• White, P.S.

Titel

Loss of heterozygosity for chromosome 14q in neuroblastoma

Ist Teil von

• Medical and pediatric oncology, 2001-01, Vol.36 (1), p.28-31

Ort / Verlag

New York: John Wiley & Sons, Inc

Erscheinungsjahr

2001

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Neuroblastoma is a genetically heterogeneous disease, with subsets of tumors demonstrating rearrangements of several genomic regions. Preliminary studies from several groups have identified loss of heterozygosity (LOH) for the long arm of chromosome 14 (14q) in 20–25% of primary neuroblastomas. Procedure To determine precisely the frequency and extent of 14q deletions, we performed LOH analysis for a large series of primary neuroblastomas using a panel of 11 highly polymorphic markers. Results LOH was detected in 83 of 372 tumors (22%). Although the majority of tumors with allelic loss demonstrated allelic loss for all informative markers, 13 cases showed LOH for only a portion of 14q. A single consensus region of deletion, which was shared by all tumors with 14q LOH, was defined within 14q23–q32 between D14S588 and the 14q telomere. Allelic loss for 14q was strongly correlated with the presence of 11q LOH (P < 0.001) and inversely correlated with MYCN amplification (P = 0.04). Conclusions LOH for 14q was evident in all clinical risk groups, indicating that this abnormality may be a universal feature of neuroblastoma tumor development. These findings suggest that a tumor suppressor gene involved in the initiation or progression of neuroblastoma is located within distal 14q. Med. Pediatr. Oncol. 36:28–31, 2001. © 2001 Wiley‐Liss, Inc.